BCO vs NBIX · P/E 25, rev $5.01B vs P/E 45, rev $2.36B
Brinks Company (BCO) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
Brinks Company (BCO) is a security & protection services company listed on US.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported BCO revenue for 2024-12-31 was $5.01B. Net income was $174.7M. Revenue was up 2.8% from 2023-12-31 to 2024-12-31. BCO currently screens at market cap $3.97B and trailing P/E 25.4.
Latest reported NBIX revenue for 2024-12-31 was $2.36B. Net income was $341.3M. Revenue was up 24.8% from 2023-12-31 to 2024-12-31. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
BCO currently screens at market cap $3.97B and trailing P/E 25.4. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the BCO and NBIX stock pages for the full models.
Not investment advice.